Dasari, Vijayendra http://orcid.org/0000-0003-2106-0945
McNeil, Lisa K.
Beckett, Kirrilee
Solomon, Matthew
Ambalathingal, George
Thuy, T. Le
Panikkar, Archana
Smith, Caitlyn
Steinbuck, Martin P.
Jakubowski, Aniela
Seenappa, Lochana M.
Palmer, Erica
Zhang, Jeff
Haqq, Christopher M. http://orcid.org/0000-0001-8600-9548
DeMuth, Peter C.
Khanna, Rajiv http://orcid.org/0000-0003-2241-0353
Article History
Received: 16 June 2022
Accepted: 28 June 2023
First Online: 8 August 2023
Competing interests
: L.K.M., M.P.S., A.J., L.M.S., E.P., J.Z., C.M.H., and P.C.D. are current or past employees of Elicio Therapeutics and as such receive salary and benefits, including ownership of stock and stock options from the company. L.K.M., M.P.S., L.M.S., J.Z., C.M.H., and P.C.D. have Amphiphile patents pending to Elicio Therapeutics. V.D. and R.K. hold international patents on EBV vaccine and immunotherapy; R.K. acts as a consultant for Atara Biotherapeutics. R.K. is on the Scientific Advisory Board of Atara Biotherapeutics. K.B., M.S., G.A., T.T.L., A.P., and C.S. declare no financial or non-financial competing interests. The authors have no other financial or non-financial competing interests including relevant affiliations or financial involvement with any organization or entity with a financial interest in, or financial conflict with the subject matter or materials discussed in the manuscript, apart from those disclosed.